DaVita Inc. (DVA) EV/Sales Ratio: 1.94x
Is DaVita Inc.’s EV/Sales ratio high or low?
DaVita Inc.'s EV/Sales ratio of 1.94x is in line with its 5-year average of 1.85x, around the middle of its 5-year range (1.53x–2.24x).
As of Monday, June 15, 2026. 7.17% above its 12-month average of 1.81x.
DVA EV/Sales Ratio Chart
DVA Average EV/Sales Ratio Chart
DVA Current vs Average EV/Sales Ratio Chart
DVA EV/Sales Ratio Metrics
EV/SALES RATIO
1.94x
EV/SALES RATIO AVG TTM
1.81x
EV/SALES RATIO AVG 3Y
1.84x
EV/SALES RATIO AVG 5Y
1.85x
EV/SALES RATIO AVG 10Y
1.76x
EV/SALES RATIO AVG 15Y
1.80x
EV/SALES RATIO AVG 20Y
1.77x
CURRENT VS TTM AVG
+7.17%
CURRENT VS 3Y AVG
+5.47%
CURRENT VS 5Y AVG
+4.92%
CURRENT VS 10Y AVG
+9.99%
CURRENT VS 15Y AVG
+8.06%
CURRENT VS 20Y AVG
+9.65%
DVA Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DaVita Inc. (DVA) | $13.40B | 1.94x | 1.81x | 1.84x | 1.85x |
| The Cooper Companies, Inc. (COO)vs › | $13.24B | 3.68x | 4.15x | 5.16x | 5.81x |
| Solventum Corporation (SOLV)vs › | $13.66B | 2.22x | 2.19x | 2.26x | 2.26x |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 2.83x | 2.73x | 4.07x | 5.90x |
| Baxter International Inc. (BAX)vs › | $10.77B | 1.63x | 1.72x | 2.17x | 2.64x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.25x | 0.26x | 0.37x | 0.45x |
| Hologic, Inc. (HOLX)vs › | $16.97B | 4.25x | 4.02x | 4.39x | 4.15x |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.03B | 2.99x | 2.79x | 3.02x | 3.79x |
| Tempus AI, Inc. (TEM)vs › | $8.35B | 6.49x | 11.43x | 12.17x | 12.17x |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.73B | 3.31x | 3.41x | 3.67x | 4.57x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
DaVita Inc. EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DaVita Inc. EV/Sales Ratio FAQ
- What is the EV/Sales ratio for DaVita Inc. (DVA)?
- The EV/Sales ratio for DVA stock is 1.94x.
- Is DaVita Inc.'s EV/Sales ratio high or low?
- DaVita Inc.'s EV/Sales ratio of 1.94x is in line with its 5-year average of 1.85x, around the middle of its 5-year range (1.53x–2.24x).
- What is the TTM average EV/Sales ratio for DaVita Inc. (DVA)?
- The TTM average EV/Sales ratio for DVA stock is 1.81x.
- What is the 3Y average EV/Sales ratio for DaVita Inc. (DVA)?
- The 3Y average EV/Sales ratio for DVA stock is 1.84x.
- What is the 5Y average EV/Sales ratio for DaVita Inc. (DVA)?
- The 5Y average EV/Sales ratio for DVA stock is 1.85x.
- What is the 10Y average EV/Sales ratio for DaVita Inc. (DVA)?
- The 10Y average EV/Sales ratio for DVA stock is 1.76x.
- What is the 15Y average EV/Sales ratio for DaVita Inc. (DVA)?
- The 15Y average EV/Sales ratio for DVA stock is 1.80x.
- What is the 20Y average EV/Sales ratio for DaVita Inc. (DVA)?
- The 20Y average EV/Sales ratio for DVA stock is 1.77x.
DaVita Inc. EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-12 | 1.94x |
| 2026-06-11 | 1.92x |
| 2026-06-10 | 1.89x |
| 2026-06-09 | 1.89x |
| 2026-06-08 | 1.86x |
| 2026-06-05 | 1.86x |
| 2026-06-04 | 1.86x |
| 2026-06-03 | 1.87x |
| 2026-06-02 | 1.84x |
| 2026-06-01 | 1.85x |
| 2026-05-29 | 1.87x |
| 2026-05-28 | 1.88x |
| 2026-05-27 | 1.87x |
| 2026-05-26 | 1.88x |
| 2026-05-22 | 1.89x |
| 2026-05-21 | 1.89x |
| 2026-05-20 | 1.88x |
| 2026-05-19 | 1.87x |
| 2026-05-18 | 1.90x |
| 2026-05-15 | 1.90x |
| 2026-05-14 | 1.86x |
| 2026-05-13 | 1.89x |
| 2026-05-12 | 1.90x |
| 2026-05-11 | 1.89x |
| 2026-05-08 | 1.89x |
| 2026-05-07 | 1.88x |
| 2026-05-06 | 1.87x |
| 2026-05-05 | 1.68x |
| 2026-05-04 | 2.04x |
| 2026-05-01 | 2.03x |
| 2026-04-30 | 2.05x |
| 2026-04-29 | 2.03x |
| 2026-04-28 | 2.02x |
| 2026-04-27 | 2.02x |
| 2026-04-24 | 2.03x |
| 2026-04-23 | 2.05x |
| 2026-04-22 | 2.03x |
| 2026-04-21 | 2.02x |
| 2026-04-20 | 2.01x |
| 2026-04-17 | 2.00x |
| 2026-04-16 | 2.00x |
| 2026-04-15 | 1.98x |
| 2026-04-14 | 2.01x |
| 2026-04-13 | 2.03x |
| 2026-04-10 | 2.02x |
| 2026-04-09 | 2.02x |
| 2026-04-08 | 2.01x |
| 2026-04-07 | 2.01x |
| 2026-04-06 | 2.02x |
| 2026-04-02 | 1.99x |
| 2026-04-01 | 2.02x |
| 2026-03-31 | 2.04x |
| 2026-03-30 | 2.03x |
| 2026-03-27 | 2.04x |
| 2026-03-26 | 2.06x |
| 2026-03-25 | 2.05x |
| 2026-03-24 | 2.04x |
| 2026-03-23 | 2.03x |
| 2026-03-20 | 2.01x |
| 2026-03-19 | 2.01x |
| 2026-03-18 | 2.01x |
| 2026-03-17 | 2.02x |
| 2026-03-16 | 2.00x |
| 2026-03-13 | 2.02x |
| 2026-03-12 | 2.04x |
| 2026-03-11 | 2.05x |
| 2026-03-10 | 2.03x |
| 2026-03-09 | 2.03x |
| 2026-03-06 | 2.02x |
| 2026-03-05 | 2.02x |
| 2026-03-04 | 2.05x |
| 2026-03-03 | 2.03x |
| 2026-03-02 | 2.04x |
| 2026-02-27 | 2.06x |
| 2026-02-26 | 2.03x |
| 2026-02-25 | 2.01x |
| 2026-02-24 | 2.02x |
| 2026-02-23 | 2.02x |
| 2026-02-20 | 2.02x |
| 2026-02-19 | 2.00x |
| 2026-02-18 | 2.00x |
| 2026-02-17 | 2.02x |
| 2026-02-13 | 2.01x |
| 2026-02-12 | 2.02x |
| 2026-02-11 | 1.98x |
| 2026-02-10 | 1.84x |
| 2026-02-09 | 1.83x |
| 2026-02-06 | 1.84x |
| 2026-02-05 | 1.89x |
| 2026-02-04 | 1.85x |
| 2026-02-03 | 1.81x |
| 2026-02-02 | 1.68x |
| 2026-01-30 | 1.67x |
| 2026-01-29 | 1.66x |
| 2026-01-28 | 1.65x |
| 2026-01-27 | 1.65x |
| 2026-01-26 | 1.66x |
| 2026-01-23 | 1.66x |
| 2026-01-22 | 1.67x |
| 2026-01-21 | 1.65x |
| 2026-01-20 | 1.64x |
| 2026-01-16 | 1.64x |
| 2026-01-15 | 1.65x |
| 2026-01-14 | 1.64x |
| 2026-01-13 | 1.64x |
| 2026-01-12 | 1.67x |
| 2026-01-09 | 1.68x |
| 2026-01-08 | 1.69x |
| 2026-01-07 | 1.68x |
| 2026-01-06 | 1.70x |
| 2026-01-05 | 1.70x |
| 2026-01-02 | 1.70x |
| 2025-12-31 | 1.69x |
| 2025-12-30 | 1.69x |
| 2025-12-29 | 1.69x |
| 2025-12-26 | 1.70x |
| 2025-12-24 | 1.70x |
| 2025-12-23 | 1.70x |
| 2025-12-22 | 1.71x |
| 2025-12-19 | 1.70x |
| 2025-12-18 | 1.71x |
| 2025-12-17 | 1.72x |
| 2025-12-16 | 1.72x |
| 2025-12-15 | 1.73x |
| 2025-12-12 | 1.74x |
| 2025-12-11 | 1.73x |
| 2025-12-10 | 1.72x |
| 2025-12-09 | 1.71x |
| 2025-12-08 | 1.71x |
| 2025-12-05 | 1.71x |
| 2025-12-04 | 1.71x |
| 2025-12-03 | 1.72x |
| 2025-12-02 | 1.72x |
| 2025-12-01 | 1.72x |
| 2025-11-28 | 1.73x |
| 2025-11-26 | 1.73x |
| 2025-11-25 | 1.74x |
| 2025-11-24 | 1.73x |
| 2025-11-21 | 1.73x |
| 2025-11-20 | 1.70x |
| 2025-11-19 | 1.70x |
| 2025-11-18 | 1.71x |
| 2025-11-17 | 1.71x |
| 2025-11-14 | 1.74x |
| 2025-11-13 | 1.75x |
| 2025-11-12 | 1.75x |
| 2025-11-11 | 1.74x |
| 2025-11-10 | 1.73x |
| 2025-11-07 | 1.75x |
| 2025-11-06 | 1.74x |
| 2025-11-05 | 1.74x |
| 2025-11-04 | 1.73x |
| 2025-11-03 | 1.72x |
| 2025-10-31 | 1.72x |
| 2025-10-30 | 1.72x |
| 2025-10-29 | 1.77x |
| 2025-10-28 | 1.68x |
| 2025-10-27 | 1.68x |
| 2025-10-24 | 1.68x |
| 2025-10-23 | 1.67x |
| 2025-10-22 | 1.68x |
| 2025-10-21 | 1.67x |
| 2025-10-20 | 1.67x |
| 2025-10-17 | 1.66x |
| 2025-10-16 | 1.66x |
| 2025-10-15 | 1.66x |
| 2025-10-14 | 1.66x |
| 2025-10-13 | 1.65x |
| 2025-10-10 | 1.65x |
| 2025-10-09 | 1.66x |
| 2025-10-08 | 1.67x |
| 2025-10-07 | 1.69x |
| 2025-10-06 | 1.67x |
| 2025-10-03 | 1.69x |
| 2025-10-02 | 1.70x |
| 2025-10-01 | 1.70x |
| 2025-09-30 | 1.70x |
| 2025-09-29 | 1.69x |
| 2025-09-26 | 1.69x |
| 2025-09-25 | 1.69x |
| 2025-09-24 | 1.71x |
| 2025-09-23 | 1.70x |
| 2025-09-22 | 1.69x |
| 2025-09-19 | 1.68x |
| 2025-09-18 | 1.69x |
| 2025-09-17 | 1.67x |
| 2025-09-16 | 1.68x |
| 2025-09-15 | 1.69x |
| 2025-09-12 | 1.70x |
| 2025-09-11 | 1.70x |
| 2025-09-10 | 1.70x |
| 2025-09-09 | 1.72x |
| 2025-09-08 | 1.71x |
| 2025-09-05 | 1.73x |
| 2025-09-04 | 1.72x |
| 2025-09-03 | 1.72x |
| 2025-09-02 | 1.72x |
| 2025-08-29 | 1.73x |
| 2025-08-28 | 1.72x |
| 2025-08-27 | 1.73x |
| 2025-08-26 | 1.74x |
| 2025-08-25 | 1.73x |
| 2025-08-22 | 1.74x |
| 2025-08-21 | 1.73x |
| 2025-08-20 | 1.73x |
| 2025-08-19 | 1.72x |
| 2025-08-18 | 1.70x |
| 2025-08-15 | 1.72x |
| 2025-08-14 | 1.71x |
| 2025-08-13 | 1.71x |
| 2025-08-12 | 1.70x |
| 2025-08-11 | 1.68x |
| 2025-08-08 | 1.68x |
| 2025-08-07 | 1.67x |
| 2025-08-06 | 1.67x |
| 2025-08-05 | 1.75x |
| 2025-08-04 | 1.79x |
| 2025-08-01 | 1.78x |
| 2025-07-31 | 1.80x |
| 2025-07-30 | 1.82x |
| 2025-07-29 | 1.83x |
| 2025-07-28 | 1.83x |
| 2025-07-25 | 1.83x |
| 2025-07-24 | 1.82x |
| 2025-07-23 | 1.86x |
| 2025-07-22 | 1.83x |
| 2025-07-21 | 1.79x |
| 2025-07-18 | 1.80x |
| 2025-07-17 | 1.81x |
| 2025-07-16 | 1.79x |
| 2025-07-15 | 1.80x |
| 2025-07-14 | 1.81x |
| 2025-07-11 | 1.81x |
| 2025-07-10 | 1.82x |
| 2025-07-09 | 1.81x |
| 2025-07-08 | 1.82x |
| 2025-07-07 | 1.81x |
| 2025-07-03 | 1.81x |
| 2025-07-02 | 1.81x |
| 2025-07-01 | 1.84x |
| 2025-06-30 | 1.81x |
| 2025-06-27 | 1.80x |
| 2025-06-26 | 1.80x |
| 2025-06-25 | 1.80x |
| 2025-06-24 | 1.80x |
| 2025-06-23 | 1.77x |
| 2025-06-20 | 1.77x |
| 2025-06-18 | 1.77x |
| 2025-06-17 | 1.77x |
| 2025-06-16 | 1.78x |
| 2025-06-13 | 1.77x |
| 2025-06-12 | 1.78x |
| 2025-06-11 | 1.78x |
| 2025-06-10 | 1.79x |
| 2025-06-09 | 1.78x |
| 2025-06-06 | 1.78x |
| 2025-06-05 | 1.78x |
| 2025-06-04 | 1.77x |
| 2025-06-03 | 1.77x |
| 2025-06-02 | 1.76x |
Showing the most recent 260 of 5,033 data points. The chart above shows the full history.
Related Metrics
About DaVita Inc.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Javier J. Rodriguez